Published in JAMA on March 26, 2014
Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. Lancet Diabetes Endocrinol (2015) 1.66
Interpreting Hemoglobin A1C in Combination With Conventional Risk Factors for Prediction of Cardiovascular Risk. Circ Cardiovasc Qual Outcomes (2015) 1.40
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol (2016) 0.94
Fructosamine and Glycated Albumin and the Risk of Cardiovascular Outcomes and Death. Circulation (2015) 0.92
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality. Diabetes (2015) 0.87
Utility of different glycemic control metrics for optimizing management of diabetes. World J Diabetes (2015) 0.85
Hemoglobin a1c and the progression of coronary artery calcification among adults without diabetes. Diabetes Care (2014) 0.84
Hemoglobin a1c levels and the risk of cardiovascular disease in people without known diabetes: a population-based cohort study in Japan. Medicine (Baltimore) (2015) 0.82
Are There Clinical Implications of Racial Differences in HbA1c? A Difference, to Be a Difference, Must Make a Difference. Diabetes Care (2016) 0.81
Associations Between Prediabetes, by Three Different Diagnostic Criteria, and Incident CVD Differ in South Asians and Europeans. Diabetes Care (2015) 0.81
Glycated hemoglobin level is significantly associated with the severity of coronary artery disease in non-diabetic adults. Lipids Health Dis (2014) 0.80
The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan. PLoS One (2015) 0.79
Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease. Diabetes Care (2016) 0.78
Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. Cardiovasc Diabetol (2015) 0.77
Whole-Body MR Imaging Including Angiography: Predicting Recurrent Events in Diabetics. Eur Radiol (2015) 0.76
Individuals with prediabetes identified by HbA1c undergoing coronary angiography have worse cardiometabolic profile than those identified by fasting glucose. Diabetol Metab Syndr (2014) 0.75
Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol (2016) 0.75
Dicarbonyl stress and atherosclerosis: is it all RAGE? Diabetes (2014) 0.75
Risk prediction of major complications in individuals with diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Obes Metab (2016) 0.75
Olive oil in the prevention and management of type 2 diabetes mellitus: a systematic review and meta-analysis of cohort studies and intervention trials. Nutr Diabetes (2017) 0.75
Hyperglycemia: a bad signature on the vascular system. Cardiovasc Diagn Ther (2015) 0.75
The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial. BMJ Open Diabetes Res Care (2015) 0.75
Observation of elevated fasting blood glucose and functional outcome after ischemic stroke in patients with and without diabetes. Oncotarget (2017) 0.75
Associations of mid-pregnancy HbA1c with gestational diabetes and risk of adverse pregnancy outcomes in high-risk Taiwanese women. PLoS One (2017) 0.75
Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes? Curr Diab Rep (2017) 0.75
Prevalence and phenotype of diabetes and prediabetes using fasting glucose vs HbA1c in a Caribbean population. J Glob Health (2017) 0.75
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med (2010) 13.25
Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med (1991) 12.89
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (2010) 11.55
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Diagnosis and classification of diabetes mellitus. Diabetes Care (2013) 6.83
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med (2001) 6.15
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. Int J Epidemiol (2010) 3.97
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 3.88
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med (2010) 3.57
A1C versus glucose testing: a comparison. Diabetes Care (2011) 2.37
Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med (2008) 2.30
Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Stat Med (2009) 2.23
Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia (2009) 1.85
Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. Diabetologia (2012) 1.01
No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population. Diabetologia (2011) 0.99
Assessing risk prediction models using individual participant data from multiple studies. Am J Epidemiol (2013) 0.95
Low HbA1c and mortality: causation and confounding. Diabetologia (2012) 0.88
Low glycated hemoglobin and liver disease in the U.S. population. Diabetes Care (2011) 0.87
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med (2011) 10.33
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet (2015) 4.46
Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. Int J Epidemiol (2010) 3.97
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med (2015) 3.47
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA (2016) 2.98
Global differences in lung function by region (PURE): an international, community-based prospective study. Lancet Respir Med (2013) 1.68
A Mendelian Randomization Study of Circulating Uric Acid and Type 2 Diabetes. Diabetes (2015) 1.52
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J (2014) 1.45
The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet (2017) 1.40
Association of Cardiometabolic Multimorbidity With Mortality. JAMA (2015) 1.32
A framework for quantifying net benefits of alternative prognostic models. Stat Med (2011) 1.08
Sex, age, and birth cohort effects in colorectal neoplasms: a cohort analysis. Ann Intern Med (2010) 1.03
Metabolic mediators of body-mass index and cardiovascular risk. Lancet (2014) 0.98
Assessing risk prediction models using individual participant data from multiple studies. Am J Epidemiol (2013) 0.95
General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2015) 0.89
Restorative yoga and metabolic risk factors: the Practicing Restorative Yoga vs. Stretching for the Metabolic Syndrome (PRYSMS) randomized trial. J Diabetes Complications (2013) 0.87
Educational class inequalities in the incidence of coronary heart disease in Europe. Heart (2016) 0.86
Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients. PLoS One (2014) 0.82
Genetic markers as instrumental variables. J Health Econ (2015) 0.80
Cardiovascular risk estimation in older persons: SCORE O.P. Eur J Prev Cardiol (2015) 0.79
A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS Med (2016) 0.79
Comparison of the performance of 2 GFR estimating equations using creatinine and cystatin C to predict adverse outcomes in elderly individuals. Am J Kidney Dis (2015) 0.79
Skeletal muscle morphology and risk of cardiovascular disease in elderly men. Eur J Prev Cardiol (2013) 0.78
Osteocalcin Is Not Associated with the Risk of Type 2 Diabetes: Findings from the EPIC-NL Study. PLoS One (2015) 0.78
Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting. Prim Care Diabetes (2015) 0.78
Association of Multiple Biomarkers of Iron Metabolism and Type 2 Diabetes: The EPIC-InterAct Study. Diabetes Care (2016) 0.77
Covariate-adjusted measures of discrimination for survival data. Biom J (2014) 0.77
Dietary patterns in relation to quality-adjusted life years in the EPIC-NL cohort. Prev Med (2015) 0.77
Association between lifestyle factors and quality-adjusted life years in the EPIC-NL cohort. PLoS One (2014) 0.77
Mortality in Postmenopausal Women by Sexual Orientation and Veteran Status. Gerontologist (2016) 0.76
Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J (2017) 0.76
C-reactive protein, fibrinogen, and cardiovascular risk. N Engl J Med (2013) 0.76
Exposure to Famine at a Young Age and Unhealthy Lifestyle Behavior Later in Life. PLoS One (2016) 0.75
Response to Letter Regarding Article, "Optimism, Cynical Hostility, and Incident Coronary Heart Disease and Mortality in the Women's Health Initiative" Circulation (2010) 0.75
Hemostatic Markers and Long-Term Risk of Intracerebral Hemorrhage in Postmenopausal Women. J Stroke Cerebrovasc Dis (2016) 0.75
Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2017) 0.75
Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States in the early 21st century. Haematologica (2017) 0.75
Language competence and communication skills in 3-year-old children after prenatal exposure to analgesic opioids. Pharmacoepidemiol Drug Saf (2017) 0.75
Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice. Prim Care Diabetes (2016) 0.75
Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol (2017) 0.75
Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. PLoS One (2017) 0.75
Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study. J Am Coll Cardiol (2016) 0.75
Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. J Surg Oncol (2017) 0.75